ZIRA: A new prognostic biomarker of estrogen receptor- positive (ER plus ) breast cancers

被引：0
|
作者：
Vendrell, J. [1 ]
Nguyen, N. T. [1 ]
Gyorffy, B. [3 ]
Leon, S. [2 ]
Grisard, E. [1 ]
Bachelot, T. [2 ]
Treilleux, I. [2 ]
Cohen, P. A. [1 ]
机构：
[1] Univ Lyon 1, Ctr Rech Cancerol Lyon, F-69365 Lyon, France
[2] Ctr Leon Berard, F-69373 Lyon, France
[3] Hungarian Acad Sci, Res Lab Pediat & Nephrol, Budapest, Hungary
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)50569-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
649
引用
收藏
页码：S155 / S155
页数：1
相关论文
共 50 条
  • [21] Expression of estrogen receptor variants in ER plus basal-type breast cancers that respond to therapy like ER- breast cancers.
    Whitworth, Pat W.
    Baron, Paul
    Beitsch, Peter D.
    Yoder, Erin
    Treece, Tina
    Audeh, M. William
    Dinjens, Winand N. M.
    Bernards, Rene
    Groenendijk, Floris
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [22] Androgen Receptor Inhibits Estrogen Receptor-α Activity and Is Prognostic in Breast Cancer
    Peters, Amelia A.
    Buchanan, Grant
    Ricciardelli, Carmela
    Bianco-Miotto, Tina
    Centenera, Margaret M.
    Harris, Jonathan M.
    Jindal, Shalini
    Segara, Davendra
    Jia, Li
    Moore, Nicole L.
    Henshall, Susan M.
    Birrell, Stephen N.
    Coetzee, Gerhard A.
    Sutherland, Robert L.
    Butler, Lisa M.
    Tilley, Wayne D.
    CANCER RESEARCH, 2009, 69 (15) : 6131 - 6140
  • [23] Triple positive (androgen receptor plus , estrogen receptor+ and HER2+) breast cancers
    Orsaria, M.
    Khelifa, S.
    Tavassoli, F.
    VIRCHOWS ARCHIV, 2011, 459 : S78 - S78
  • [24] Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers
    Floris H. Groenendijk
    Tina Treece
    Erin Yoder
    Paul Baron
    Peter Beitsch
    William Audeh
    Winand N. M. Dinjens
    Rene Bernards
    Pat Whitworth
    npj Breast Cancer, 5
  • [25] Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers
    Groenendijk, Floris H.
    Treece, Tina
    Yoder, Erin
    Baron, Paul
    Beitsch, Peter
    Audeh, William
    Dinjens, Winand N. M.
    Bernards, Rene
    Whitworth, Pat
    NPJ BREAST CANCER, 2019, 5 (1)
  • [26] Prognostic Significance of Multifocal Lesion in ER plus Breast Cancers
    Liang, Y.
    Li, X.
    Wang, J.
    Huo, L.
    Albarracin, C.
    Gong, Y.
    Wu, Y.
    LABORATORY INVESTIGATION, 2014, 94 : 65A - 65A
  • [27] Prognostic Significance of Multifocal Lesion in ER plus Breast Cancers
    Liang, Y.
    Li, X.
    Wang, J.
    Huo, L.
    Albarracin, C.
    Gong, Y.
    Wu, Y.
    MODERN PATHOLOGY, 2014, 27 : 65A - 65A
  • [28] Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER plus ) metastatic breast cancers (MBC).
    Basu, Gargi D.
    White, Tracey
    LoBello, Janine R.
    Kurdoglu, Ahmet
    Trent, Jeffrey M.
    Halbert, Matthew J.
    Royce, Thomas
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Estrogen Receptor (ER) mRNA and ER -Related Gene Expression in Breast Cancers That Are 1%-10% ER -Positive by Immunohistochemistry.
    Iwamoto, T.
    Booser, D.
    Valero, V.
    Murray, J. L.
    Koenig, K.
    Esteva, F. J.
    Ueno, N. T.
    Zhang, J.
    Shi, W.
    Qi, Y.
    Matsuoka, J.
    Hortobagyi, G. N.
    Hatzis, C.
    Symmans, W. F.
    Pusztai, L.
    CANCER RESEARCH, 2011, 71
  • [30] Estrogen drives the therapeutic hormonal response in ER plus breast cancers
    Hugh, Judith
    Haddon, Lacey
    Githaka, John Maringa
    Hu, Xiuying
    Bigras, Gilbert
    Loney, Brittney
    Hanson, John
    Gabos, Zsolt
    Huang, Fleur
    Hitt, Mary
    McManus, Kirk
    Dabbs, Kelly
    Mackey, John
    CANCER RESEARCH, 2020, 80 (04)
12345